Cargando…

The dark side of mRNA translation and the translation machinery in glioblastoma

Among the different types of cancer affecting the central nervous system (CNS), glioblastoma (GB) is classified by the World Health Organization (WHO) as the most common and aggressive CNS cancer in adults. GB incidence is more frequent among persons aged 45–55 years old. GB treatments are based on...

Descripción completa

Detalles Bibliográficos
Autores principales: Montiel-Dávalos, Angélica, Ayala, Yeniffer, Hernández, Greco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042294/
https://www.ncbi.nlm.nih.gov/pubmed/36994107
http://dx.doi.org/10.3389/fcell.2023.1086964
_version_ 1784912901590482944
author Montiel-Dávalos, Angélica
Ayala, Yeniffer
Hernández, Greco
author_facet Montiel-Dávalos, Angélica
Ayala, Yeniffer
Hernández, Greco
author_sort Montiel-Dávalos, Angélica
collection PubMed
description Among the different types of cancer affecting the central nervous system (CNS), glioblastoma (GB) is classified by the World Health Organization (WHO) as the most common and aggressive CNS cancer in adults. GB incidence is more frequent among persons aged 45–55 years old. GB treatments are based on tumor resection, radiation, and chemotherapies. The current development of novel molecular biomarkers (MB) has led to a more accurate prediction of GB progression. Moreover, clinical, epidemiological, and experimental studies have established genetic variants consistently associated with the risk of suffering GB. However, despite the advances in these fields, the survival expectancy of GB patients is still shorter than 2 years. Thus, fundamental processes inducing tumor onset and progression remain to be elucidated. In recent years, mRNA translation has been in the spotlight, as its dysregulation is emerging as a key cause of GB. In particular, the initiation phase of translation is most involved in this process. Among the crucial events, the machinery performing this phase undergoes a reconfiguration under the hypoxic conditions in the tumor microenvironment. In addition, ribosomal proteins (RPs) have been reported to play translation-independent roles in GB development. This review focuses on the research elucidating the tight relationship between translation initiation, the translation machinery, and GB. We also summarize the state-of-the-art drugs targeting the translation machinery to improve patients’ survival. Overall, the recent advances in this field are shedding new light on the dark side of translation in GB.
format Online
Article
Text
id pubmed-10042294
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100422942023-03-28 The dark side of mRNA translation and the translation machinery in glioblastoma Montiel-Dávalos, Angélica Ayala, Yeniffer Hernández, Greco Front Cell Dev Biol Cell and Developmental Biology Among the different types of cancer affecting the central nervous system (CNS), glioblastoma (GB) is classified by the World Health Organization (WHO) as the most common and aggressive CNS cancer in adults. GB incidence is more frequent among persons aged 45–55 years old. GB treatments are based on tumor resection, radiation, and chemotherapies. The current development of novel molecular biomarkers (MB) has led to a more accurate prediction of GB progression. Moreover, clinical, epidemiological, and experimental studies have established genetic variants consistently associated with the risk of suffering GB. However, despite the advances in these fields, the survival expectancy of GB patients is still shorter than 2 years. Thus, fundamental processes inducing tumor onset and progression remain to be elucidated. In recent years, mRNA translation has been in the spotlight, as its dysregulation is emerging as a key cause of GB. In particular, the initiation phase of translation is most involved in this process. Among the crucial events, the machinery performing this phase undergoes a reconfiguration under the hypoxic conditions in the tumor microenvironment. In addition, ribosomal proteins (RPs) have been reported to play translation-independent roles in GB development. This review focuses on the research elucidating the tight relationship between translation initiation, the translation machinery, and GB. We also summarize the state-of-the-art drugs targeting the translation machinery to improve patients’ survival. Overall, the recent advances in this field are shedding new light on the dark side of translation in GB. Frontiers Media S.A. 2023-03-13 /pmc/articles/PMC10042294/ /pubmed/36994107 http://dx.doi.org/10.3389/fcell.2023.1086964 Text en Copyright © 2023 Montiel-Dávalos, Ayala and Hernández. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Montiel-Dávalos, Angélica
Ayala, Yeniffer
Hernández, Greco
The dark side of mRNA translation and the translation machinery in glioblastoma
title The dark side of mRNA translation and the translation machinery in glioblastoma
title_full The dark side of mRNA translation and the translation machinery in glioblastoma
title_fullStr The dark side of mRNA translation and the translation machinery in glioblastoma
title_full_unstemmed The dark side of mRNA translation and the translation machinery in glioblastoma
title_short The dark side of mRNA translation and the translation machinery in glioblastoma
title_sort dark side of mrna translation and the translation machinery in glioblastoma
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042294/
https://www.ncbi.nlm.nih.gov/pubmed/36994107
http://dx.doi.org/10.3389/fcell.2023.1086964
work_keys_str_mv AT montieldavalosangelica thedarksideofmrnatranslationandthetranslationmachineryinglioblastoma
AT ayalayeniffer thedarksideofmrnatranslationandthetranslationmachineryinglioblastoma
AT hernandezgreco thedarksideofmrnatranslationandthetranslationmachineryinglioblastoma
AT montieldavalosangelica darksideofmrnatranslationandthetranslationmachineryinglioblastoma
AT ayalayeniffer darksideofmrnatranslationandthetranslationmachineryinglioblastoma
AT hernandezgreco darksideofmrnatranslationandthetranslationmachineryinglioblastoma